ByramConnect™ for Employers
Diabetes Digital Solution for Healthier Employees1,2,3
ByramConnect™, powered by WellDoc®, provides a 24/7 digital coach that can help your employees better self-manage their diabetes, resulting in reductions in their A1C, leading to healthier, more productive lives while helping to reduce your costs1,2,3
CONTACT US
Features and Benefits
Give Your Employees a “Coach in Your Pocket” for Improved Self-Care
Empower your staff with the tools and guidance they need to analyze, guide, and improve their daily diabetes self-management.
Individualized, 24/7 Real-time Feedback and Actionable Insights from >950,000 messages to guide employees every step of the way to manage their unique needs
Artificial Intelligence that monitors, analyzes, and identifies patterns and trends for blood glucose, food, blood pressure, medications, weight, activity, sleep & more
Certified Diabetes Care & Education Specialists available for additional support
Hub for collecting data
Watch How ByramConnect™ Can Improve Overall Health & Lower Costs1,2,3
To view with Open Captioning Click Here
Cost Analysis
What If You Could Lower A1C 1-2 Points and Save $3k - $5.2k Annually on Your Diabetic Employees?
A1C Reduction and Cost Savings3
*BlueStar Rx/OTC is an FDA-cleared medical device, is indicated for use by patients aged 18 and older who have Type 1 or Type 2 diabetes and their healthcare providers. For full labeling information, visit www.welldoc.com.
Analysis of Costs in Partnership with IBM Watson Health1
Starting and ending A1C values were provided from 3,000+ app users to IBM Watson Health. User data was run through IBM’s MarketScan claims database of more than 80 million individuals to correlate cost savings due to a reduction of:
Cost Savings
$3,048-
$5,244
(Per Person Anually)
Hospitalizations, ER visits, and HCP office visits
Cost of medical devices, supplies, and medications
Cost of co-morbid conditions (weight, hypertension, etc.)
Annual Savings by Starting A1C Bands
A1C bands
estimated cost savings (per patient annually)
estimated cost savings (per patient, annually)
Studies in Type-2 Diabetes
3-Month randomized-controlled clinical trial
In a prospective, randomized, controlled study, Quinn et al. (Diabetes Technology and Therapeutics, 2008) found that individuals whose A1C levels were greater than or equal to 7.5% within most recent three months and received BlueStar software experienced an average decrease in A1C of 2.03%. Patients in the control group obtained an average A1C reduction of 0.68% (P < 0.02, one-tailed). Of the intervention patients, 84% had medications titrated or changed by their HCP compared to controls (23%, P=0.002).
READ ABSTRACT12-Month randomized-controlled clinical trial
In a prospective, randomized, controlled study, Quinn et al. (Diabetes Care, 2011) found that, individuals with type 2 diabetes whose A1C levels were poorly controlled (>9.0%) or abnormal (7.5-8.9%) at the time of enrollment, and who were randomized to use a mobile phone app to help them manage their diabetes in addition to usual care, improved A1C by an average 1.9%, compared with 0.7% improvement in persons randomized to usual care alone, a difference of 1.2% (P < 0.001) over 12 months.
READ ABSTRACTDigital Diabetes Solution Addresses the Challenges with Diabetes
More than 60+ peer-reviewed randomized clinical trials, studies, whitepapers, posters and publications highlight the ability of this diabetes digital health solution to:
Improve Staff Health & Productivity
With lower A1C and better diabetes self-management
Generate Cost Savings
Estimated cost savings ranging from $3,048 – $5,244 per user annually for A1C >8 resulting from managing glycemic variability1
Increase Medication Adherence
Medication reminder is among the most frequently used features by App users
Insights for Providers and Care Teams
Engaged users can share their data and insights with physicians and care teams
The ByramConnect™ app, powered by BlueStar®, is indicated for use by patients aged 18 and older who have Type 1 or Type 2 diabetes and their healthcare providers. The app is not intended to replace the care provided by a licensed healthcare professional. The app should not be used by patients with gestational diabetes or patients using an insulin pump. BlueStar® is a Welldoc®, Inc. patented system.
Research is conducted by Welldoc® utilizing BlueStar®* product data on file in conjunction with Welldoc partners. Byram Connect™ is equivalent to the Welldoc BlueStar product.
*BlueStar Rx/OTC is an FDA-cleared medical device, is indicated for use by patients aged 18 and older who have Type 1 or Type 2 diabetes and their healthcare providers. For full labeling information, visit www.welldoc.com.
1 IBM Watson Health. Estimating the economic value of a digital therapeutic in type 2 diabetes. Welldoc-sponsored report 2018. Published August 2018.
2 Tang PY, Duni J, Peeples MM, et al. Complementarity of digital health and peer support: “This Is What’s Coming.” Front Clin Diabetes Health. 2021;2. doi:10.3389/fcdhc.2021.646963
3 Quinn CC, Sareh PL, Shardell ML, Terrin ML, Barr EA, Gruber-Baldini AL. Mobile Diabetes Intervention for Glycemic Control. Journal of Diabetes Science and Technology. 2014;8(2):362-370. doi:10.1177/1932296813514503
4 Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017 Estimates of Diabetes and Its Burden in the United States Background.; 2020. National Diabetes Statistics Report
5 Mayo Clinic Proceedings Medication Adherence: WHO Cares?
